Verma et al.(4)
|
Breast |
Ado-trastuzumab emtansine (T-DM1) |
Antibody-drug conjugate against Her2+ cells |
Metastatic Her2+ breast cancer, after failing trastuzumab and taxane |
Improved PFS and overall survival compared with lapatinib and capecitabine |
Registered in Brazil. Not available in Brazilian Public Health System |
Swain et al.(5)
|
Breast |
Pertuzumab |
Her2 inhibition |
Metastatic Her2+ breast cancer |
Improved PFS and overall survival compared with trastuzumab and taxane |
Registered in Brazil. Not available in Brazilian Public Health System |
Piccart et al.(6)
|
Breast |
Everolimus |
mTOR inhibitor |
Metastatic HR+ and Her2- breast cancer in combination with exemestane |
Improved PFS compared with second line exemestane alone |
Registered in Brazil. Not available in Brazilian Public Health System |
Turner et al.(7)
|
Breast |
Palbociclib |
CDK4 and CDK6 inhibitor |
Metastatic HR+ and Her2- breast cancer in combination with fulvestrant |
Improved PFS compared with second line Fulvestrant alone |
Not registered in Brazil |
Tewari et al.(8)
|
Cervix |
Bevacizumab |
VEGF inhibitor |
Metastatic cervical cancer |
Improved overall survival when added to chemotherapy |
Registered in Brazil. Not available in the Brazilian Public Health System |
Grothey et al.(9)
|
Colorectal |
Regorafenib |
Multikinase inhibitor |
Previously treated metastatic colorectal cancer |
Modest improvement in overall survival compared with supportive care alone |
Not registered in Brazil |
Fuchs et al.(10)
|
Gastric |
Ramucirumab |
VEGFR2 antagonist |
Inoperable gastric or gastroesophageal junction adenocarcinoma after prior chemotherapy |
Improved survival compared with placebo |
Not registered in Brazil |
Demetri et al.(11)
|
GIST |
Regorafenib |
Multikinase inhibitor |
Metastatic GIST after standard treatment with imatinib and sunitinib |
Improved PFS compared with placebo |
Not registered in Brazil |
Wu et al.(12); Sequist et al.(13)
|
Lung |
Afatinib |
EGFR inhibitor |
Metastatic NSCLC with EGFR exon 19 deletion or L858R EGFR mutation |
Improved PFS compared with gemcitabine and cisplatin or with cisplatin and pemetrexed |
Not registered in Brazil |
Shaw et al.(14,15)
|
Lung |
Crizotinib |
ALK inhibitor, ROS1 inhibitor |
Metastatic NSCLC with ALK-EML4 fusion, or with ROS1 rearrangement |
Improved PFS compared with pemetrexed in platinum refractory disease |
Not registered in Brazil |
Shaw et al.(16)
|
Lung |
Ceritinib |
ALK inhibitor |
Metastatic ALK-rearranged NSCLC |
Responses in naïve and crizotinib pretreated disease |
Not registered in Brazil |
Chapman et al.(17)
|
Melanoma |
Vemurafenib |
BRAF inhibitor |
Metastatic melanoma with BRAF V600E mutation |
Improved overall survival and PFS compared with Dacarbazine |
Registered in Brazil. Not available in the Brazilian Public Health System |
Robert et al.(18)
|
Melanoma |
Dabrafenib |
BRAF inhibitor |
Metastatic melanoma BRAF V600E mutation |
Improved overall survival when combined with Trametinib, compared with Vemurafenib |
Not registered in Brazil. |
Robert et al.(18)
|
Melanoma |
Trametinib |
MEK inhibitor |
Metastatic Melanoma with BRAF V600E or V600K mutation |
Improved overall survival when combined with Dabrafenib, compared with Vemurafenib |
Not registered in Brazil |
Ledermann et al.(19)
|
Ovary |
Olaparib |
Inhibitor of poly (ADP-ribose) polymerase |
BRCA mutated advanced ovarian cancer |
Improved PFS compared with placebo in platinum sensitive relapse |
Not registered in Brazil |
Brose et al.(20)
|
Thyroid |
Sorafenib |
Multi-kinase inhibitor |
Metastatic differentiated thyroid cancer refractory to radioactive iodine |
Improved PFS compared with placebo |
Not registered in Brazil for this indication |
Schlumberger et al.(21)
|
Thyroid |
Lenvatinib |
VEGF receptor inhibitor, PDGFR inhibitor, RET and KIT |
Metastatic differentiated thyroid cancer refractory to radioactive iodine |
Improved PFS compared with placebo |
Not registered in Brazil |
Elisei et al.(22)
|
Medullary thyroid |
Cabozantinib |
MET, VEGFR2 and RET inhibitor |
Progressive metastatic medullary thyroid cancer |
Improved PFS compared with placebo |
Not registered in Brazil |
Wells et al.(23)
|
Medullary thyroid |
Vandetanib |
RET kinase inhibitor and VEGF inhibitor |
Progressive metastatic medullary thyroid cancer |
Improved PFS compared with placebo |
Not registered in Brazil |